vs
奥尼兰姆制药（ALNY）与Rackspace Technology, Inc.（RXT）财务数据对比。点击上方公司名可切换其他公司
奥尼兰姆制药的季度营收约是Rackspace Technology, Inc.的1.7倍（$1.2B vs $682.8M），奥尼兰姆制药净利率更高（17.6% vs -4.8%，领先22.4%），奥尼兰姆制药同比增速更快（96.4% vs -0.4%），过去两年奥尼兰姆制药的营收复合增速更高（33.0% vs -0.6%）
奥尼兰姆制药是美国生物制药企业，2002年成立，总部位于马萨诸塞州剑桥市，专注于研发及商业化针对基因明确疾病的RNA干扰（RNAi）疗法，2016年入选福布斯「100家最具创新力成长企业」榜单。
Rackspace Technology, Inc.是总部位于美国得克萨斯州圣安东尼奥的云计算企业，在弗吉尼亚州雷斯顿以及澳大利亚、加拿大、英国、印度、迪拜、瑞士、荷兰、德国、新加坡、墨西哥、中国香港等多个国家和地区设有办事处，数据中心分布于全球多个主要城市，为客户提供专业的云计算相关服务。
ALNY vs RXT — 直观对比
营收规模更大
ALNY
是对方的1.7倍
$682.8M
营收增速更快
ALNY
高出96.8%
-0.4%
净利率更高
ALNY
高出22.4%
-4.8%
两年增速更快
ALNY
近两年复合增速
-0.6%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.2B | $682.8M |
| 净利润 | $206.0M | $-32.7M |
| 毛利率 | 82.2% | 17.6% |
| 营业利润率 | 23.0% | -0.5% |
| 净利率 | 17.6% | -4.8% |
| 营收同比 | 96.4% | -0.4% |
| 净利润同比 | — | 41.6% |
| 每股收益（稀释后） | $1.51 | $-0.13 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ALNYRXT
| Q1 26 | $1.2B | — | ||
| Q4 25 | $1.1B | $682.8M | ||
| Q3 25 | $1.2B | $671.2M | ||
| Q2 25 | $773.7M | $666.3M | ||
| Q1 25 | $594.2M | $665.4M | ||
| Q4 24 | $593.2M | $685.6M | ||
| Q3 24 | $500.9M | $675.8M | ||
| Q2 24 | $659.8M | $684.9M |
净利润ALNYRXT
| Q1 26 | $206.0M | — | ||
| Q4 25 | $186.4M | $-32.7M | ||
| Q3 25 | $251.1M | $-67.1M | ||
| Q2 25 | $-66.3M | $-54.5M | ||
| Q1 25 | $-57.5M | $-71.5M | ||
| Q4 24 | $-83.8M | $-56.0M | ||
| Q3 24 | $-111.6M | $-186.6M | ||
| Q2 24 | $-16.9M | $25.0M |
毛利率ALNYRXT
| Q1 26 | 82.2% | — | ||
| Q4 25 | 75.6% | 17.6% | ||
| Q3 25 | 84.2% | 19.4% | ||
| Q2 25 | 81.6% | 19.4% | ||
| Q1 25 | 88.2% | 19.1% | ||
| Q4 24 | 82.7% | 19.2% | ||
| Q3 24 | 83.6% | 20.3% | ||
| Q2 24 | 89.8% | 19.2% |
营业利润率ALNYRXT
| Q1 26 | 23.0% | — | ||
| Q4 25 | 12.0% | -0.5% | ||
| Q3 25 | 29.5% | -5.1% | ||
| Q2 25 | -2.1% | -3.8% | ||
| Q1 25 | 3.0% | -5.8% | ||
| Q4 24 | -17.7% | -4.2% | ||
| Q3 24 | -15.4% | -25.7% | ||
| Q2 24 | 7.4% | -7.9% |
净利率ALNYRXT
| Q1 26 | 17.6% | — | ||
| Q4 25 | 17.0% | -4.8% | ||
| Q3 25 | 20.1% | -10.0% | ||
| Q2 25 | -8.6% | -8.2% | ||
| Q1 25 | -9.7% | -10.7% | ||
| Q4 24 | -14.1% | -8.2% | ||
| Q3 24 | -22.3% | -27.6% | ||
| Q2 24 | -2.6% | 3.7% |
每股收益（稀释后）ALNYRXT
| Q1 26 | $1.51 | — | ||
| Q4 25 | $1.44 | $-0.13 | ||
| Q3 25 | $1.84 | $-0.28 | ||
| Q2 25 | $-0.51 | $-0.23 | ||
| Q1 25 | $-0.44 | $-0.31 | ||
| Q4 24 | $-0.66 | $-0.20 | ||
| Q3 24 | $-0.87 | $-0.82 | ||
| Q2 24 | $-0.13 | $0.11 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.7B | $105.8M |
| 总债务越低越好 | — | $2.7B |
| 股东权益账面价值 | $1.1B | $-1.2B |
| 总资产 | $5.1B | $2.8B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ALNYRXT
| Q1 26 | $1.7B | — | ||
| Q4 25 | $1.7B | $105.8M | ||
| Q3 25 | $1.5B | $99.5M | ||
| Q2 25 | $1.1B | $103.9M | ||
| Q1 25 | $1.0B | $128.0M | ||
| Q4 24 | $966.4M | $144.0M | ||
| Q3 24 | $1.1B | $157.1M | ||
| Q2 24 | $968.5M | $190.2M |
总债务ALNYRXT
| Q1 26 | — | — | ||
| Q4 25 | — | $2.7B | ||
| Q3 25 | — | $2.8B | ||
| Q2 25 | — | $2.8B | ||
| Q1 25 | — | $2.8B | ||
| Q4 24 | — | $2.8B | ||
| Q3 24 | — | $2.8B | ||
| Q2 24 | — | $2.9B |
股东权益ALNYRXT
| Q1 26 | $1.1B | — | ||
| Q4 25 | $789.2M | $-1.2B | ||
| Q3 25 | $233.9M | $-1.2B | ||
| Q2 25 | $250.6M | $-1.1B | ||
| Q1 25 | $115.4M | $-1.1B | ||
| Q4 24 | $67.1M | $-1.0B | ||
| Q3 24 | $32.4M | $-949.7M | ||
| Q2 24 | $-3.1M | $-756.2M |
总资产ALNYRXT
| Q1 26 | $5.1B | — | ||
| Q4 25 | $5.0B | $2.8B | ||
| Q3 25 | $4.9B | $2.8B | ||
| Q2 25 | $4.6B | $2.9B | ||
| Q1 25 | $4.2B | $3.0B | ||
| Q4 24 | $4.2B | $3.1B | ||
| Q3 24 | $4.2B | $3.1B | ||
| Q2 24 | $4.0B | $3.4B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $59.7M |
| 自由现金流经营现金流 - 资本支出 | — | $56.0M |
| 自由现金流率自由现金流/营收 | — | 8.2% |
| 资本支出强度资本支出/营收 | — | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $90.6M |
8季度趋势，按日历期对齐
经营现金流ALNYRXT
| Q1 26 | — | — | ||
| Q4 25 | $163.6M | $59.7M | ||
| Q3 25 | $325.1M | $70.7M | ||
| Q2 25 | $153.7M | $8.4M | ||
| Q1 25 | $-118.3M | $12.6M | ||
| Q4 24 | $-94.7M | $54.3M | ||
| Q3 24 | $43.7M | $51.8M | ||
| Q2 24 | $124.2M | $24.1M |
自由现金流ALNYRXT
| Q1 26 | — | — | ||
| Q4 25 | $140.3M | $56.0M | ||
| Q3 25 | $313.0M | $42.7M | ||
| Q2 25 | $139.4M | $-12.4M | ||
| Q1 25 | $-127.3M | $4.3M | ||
| Q4 24 | $-103.8M | $34.4M | ||
| Q3 24 | $39.5M | $27.3M | ||
| Q2 24 | $116.1M | $-14.5M |
自由现金流率ALNYRXT
| Q1 26 | — | — | ||
| Q4 25 | 12.8% | 8.2% | ||
| Q3 25 | 25.1% | 6.4% | ||
| Q2 25 | 18.0% | -1.9% | ||
| Q1 25 | -21.4% | 0.6% | ||
| Q4 24 | -17.5% | 5.0% | ||
| Q3 24 | 7.9% | 4.0% | ||
| Q2 24 | 17.6% | -2.1% |
资本支出强度ALNYRXT
| Q1 26 | — | — | ||
| Q4 25 | 2.1% | 0.5% | ||
| Q3 25 | 1.0% | 4.2% | ||
| Q2 25 | 1.8% | 3.1% | ||
| Q1 25 | 1.5% | 1.2% | ||
| Q4 24 | 1.5% | 2.9% | ||
| Q3 24 | 0.8% | 3.6% | ||
| Q2 24 | 1.2% | 5.6% |
现金转化率ALNYRXT
| Q1 26 | — | — | ||
| Q4 25 | 0.88× | — | ||
| Q3 25 | 1.29× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.96× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ALNY
| AMVUTTRA | $889.9M | 76% |
| GIVLAARI | $74.4M | 6% |
| OXLUMO | $51.3M | 4% |
| Royalty revenue | $49.0M | 4% |
| Regeneron Pharmaceuticals | $46.3M | 4% |
| Roche | $35.6M | 3% |
| ONPATTRO | $20.5M | 2% |
RXT
| Public Cloud Services Segment | $442.2M | 65% |
| Private Cloud Service Segment | $240.6M | 35% |
